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The apical membrane of intestinal epithelial cells har-
bors a unique isozyme of cGMP-dependent protein ki-
nase (cGK type II) which acts as a key regulator of ion
transport systems, including the cystic fibrosis trans-
membrane conductance regulator (CFTR)-chloride
channel. To explore the mechanism of cGK II mem-
brane-anchoring, recombinant cGK II was expressed
stably in HEK 293 cells or transiently in COS-1 cells. In
both cell lines, cGK II was found predominantly in the
particulate fraction. Immunoprecipitation of solubi-
lized cGK II did not reveal any other tightly associated
proteins, suggesting a membrane binding motif within
cGK II itself. The primary structure of cGK II is devoid
of hydrophobic transmembrane domains; cGK II does,
however, contain a penultimate glycine, a potential
acceptor for a myristoyl moiety. Metabolic labeling
showed that cGK II was indeed able to incorporate
[3H]myristate. Moreover, incubation of cGK II-express-
ing 293 cells with the myristoylation inhibitor 2-hy-
droxymyristic acid (1 mM) significantly increased the
proportion of cGK II in the cytosol from 10 6 5 to 35 6
4%. Furthermore, a nonmyristoylated cGK II Gly23 Ala
mutant was localized predominantly in the cytosol after
transient expression in COS-1 cells. The absence of the
myristoyl group did not affect the specific enzyme activ-
ity or the Ka for cGMP and only slightly enhanced the
thermal stability of cGK II. These results indicate that
N-terminal myristoylation fulfills a crucial role in di-
recting cGK II to the membrane.
Cyclic GMP-dependent protein kinases (cGK)1 play an im-
portant role in cGMP-mediated signaling pathways which are
triggered by various hormones and neurotransmitters includ-
ing nitric oxide (NO), natriuretic peptides, and guanylin (1, 2).
In mammalian tissues, two types of cGK have been identified.
Type I cGK, consisting of a and b isoforms, possible splice
variants of a single gene, is more generally expressed and acts
as a key regulator of cardiovascular homeostasis (1, 2). In
contrast, type II cGK was described originally as an intestine-
specific form (3). Molecular cloning demonstrated that cGK II is
indeed a distinct gene product expressed predominantly in
epithelial cells of the intestine (4), although its mRNA was also
detected in kidney and brain (4–6). Its widespread distribution
in various areas of the brain suggests an important role of cGK
II in the NO/cGMP signaling in the central nervous system (6).
In the intestine, cGMP is involved in the regulation of ion
and water transport. It inhibits the uptake of NaCl and stim-
ulates the secretion of chloride by activating the cystic fibrosis
transmembrane conductance regulator (CFTR), a chloride
channel which is mutated in CF patients (7, 8). Heat-stable
enterotoxins increase cGMP and elicit a severe secretory diar-
rhea by activating an intestine-specific isoform of guanylyl
cyclase (9). Guanylin, a heat-stable enterotoxin-like peptide,
may function as the physiological activator of the cGMP-medi-
ated signaling pathway in intestine (10). Recent electrophysi-
ological and localization studies suggest a key role for cGK II as
a mediator of the cGMP-provoked intestinal chloride secretion
(8, 11, 12).
The positioning of cGK II in the apical membrane of the
enterocyte, facilitating its interaction with transport systems
in the same compartment, may contribute importantly to its
efficacy as an ion transport regulator. However, the mode of
cGK II membrane anchoring has not been elucidated. The
primary sequence of cGK II, like the sequence of type I cGK, a
known cytosolic and/or peripheral protein, reveals no obvious
hydrophobic transmembrane domains (2, 4). Instead, the mem-
brane localization of cGK II might be determined by its asso-
ciation with a distinct anchor protein. A family of anchor pro-
teins exists for the regulatory subunit of cAMP-dependent
protein kinase (cAK) (13), and the intermediate filament pro-
tein vimentin may function as a receptor for cGK I (14). Alter-
natively, cGK II itself may acquire hydrophobic properties
through the attachment of a lipid moiety. A number of proteins
involved in signal transduction, e.g. Src, Ras, and trimeric
G-proteins require lipid modifications like myristoylation,
palmitoylation, or isoprenylation for membrane binding (15).
Type II cGK lacks a consensus sequence for isoprenylation, but
the penultimate glycine in cGK II might serve as an acceptor
for a myristoyl group (15). We report here that recombinant
cGK II expressed in HEK-293 and COS-1 cells is indeed myr-
istoylated and that this lipidation is required for its attachment
to the membrane.
EXPERIMENTAL PROCEDURES
Materials—Cell culture media and G418 sulfate (GeneticinR) were
obtained from Life Technologies, Inc., 3-isobutyl-1-methylxanthine and
2-hydroxymyristic acid from Sigma, L-[35S]methionine (Tran35S-la-
belTM) from ICN, [3H]myristate (54 Ci/mmol), [3H]palmitate (50 Ci/
mmol), the enhanced chemiluminescence (ECL) system and AmplifyTM
from Amersham, protein A-Sepharose from Pierce, and DEAE-dextran
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from Pharmacia Biotech Inc. A polyclonal cGK II antibody, raised
against recombinant rat cGK II expressed in Escherichia coli, was
prepared as described (11). Preparation of the cGK II expression vector
pRc/CMV-cGK II was described earlier (4). The cGK substrate peptide
2A3 (RRVSKQE) and the Walsh inhibitor peptide (PKI-(5–24)-amide)
were synthesized by D. Palm (University of Wu¨rzburg, Germany). Pu-
rified oligonucleotides were obtained from Eurogentec.
Construction of a Nonmyristoylatable cGK II Mutant G2A—A cGKII-
G2A mutant in which Gly2 was changed to Ala was generated directly
from the pRc/CMV-cGK II plasmid using the TransformerTM site-di-
rected mutagenesis kit (Clontech), with CTGAGCAACATGGCAAATG-
GTTCAGTG as the mutagenic primer and CACTAGTTCTAGTGGGC-
CCTATTC as the selection primer targeted to the unique XbaI site. The
mutation was confirmed by sequencing the G2A plasmid using the
SequenaseR DNA Sequencing Kit (United States Biochemical Corp.).
Expression of cGK II in HEK 293 and COS-1 Cells—The pRc/CMV-
cGK II expression vector was transfected into HEK 293 cells as de-
scribed (4). Stable transfectants were selected from individual clones
growing in the presence of G418 sulfate. The clone expressing the
highest level of cGK II was used throughout this study and cultured in
the presence of G418 sulfate (200 mg/ml). COS-1 cells were transfected
1 day after subculturing at 80–90% confluency, by means of a 20-min
incubation at 25 °C with 0.5 mg/ml DEAE-dextran in phosphate-buff-
ered saline containing 1 mg of vector DNA per 106 cells. Cells were
harvested 2 days after transfection as described for the individual
analyses that follow.
Membrane Isolation and Subcellular Fractionation—Confluent cells
were washed twice with ice-cold phosphate-buffered saline, scraped
with a rubber policeman in buffer A (150 mM NaCl, 10 mM NaPO4, pH
7.4, 1 mM EDTA, 100 mg/ml trypsin inhibitor, and 20 mg/ml leupeptin),
and processed directly or frozen in liquid N2 and stored at 280 °C. The
cells were homogenized by brief sonication (three bursts of 3 s, peak-
to-peak amplitude 15–20 mm). Cytosol and membranes were separated
by centrifugation at 150,000 3 g for 60 min at 4 °C in an airfuge.
Metabolic Labeling and Immunoprecipitation of cGK II—Confluent
cells were incubated at 37 °C for 4 h in Dulbecco’s modified Eagle’s
medium or in Dulbecco’s modified Eagle’s medium without methionine,
supplemented with 2% fetal calf serum and either 0.1 mCi/ml L-[35S]me-
thionine, 0.25 mCi/ml [3H]myristate, or 0.5 mCi/ml [3H]palmitate. La-
beled cells were washed twice with phosphate-buffered saline, and
solubilized for 5 min with 1% Triton X-100 in ice-cold buffer A in the
presence of 0.5 M NaCl. After a short spin (5 min at 20,000 3 g), the
supernatant fluid was incubated for 30 min at 0 °C with cGK II anti-
body (1:200) and centrifuged for 45 min at 20,000 3 g. The proteins
bound to the antibody were precipitated with protein A-Sepharose (5 ml
of packed gel/ml of antiserum) and visualized by indirect autoradiogra-
phy using AmplifyTM as described (16).
Immunoblotting and Protein Kinase Assays—Immunoblotting was
performed as described earlier (16). Samples (10–20 mg of protein) were
separated by SDS-PAGE and blotted onto nitrocellulose. Blots were
incubated with the cGK II antibody (1:3000), labeled using the ECL
method, and cGK II was quantitated by densitometric scanning
(Bio-Rad, model 620).
Protein kinase activity was determined by incubating samples (5–
10-ml aliquots containing 5–10 mg of protein) at 30 °C for 10 min in 50
ml of 20 mM Tris-HCl, pH 7.4, 10 mM MgCl2, 5 mM b-mercaptoethanol,
0.1 mM 3-isobutyl-1-methylxanthine, 200 nM protein kinase A inhibitor,
0.1 mM [g-32P]ATP (200 cpm/pmol), and a 0.1 mg/ml concentration of a
cGK-specific substrate peptide 2A3 (RRKVSKQE) as described (17). To
reduce high nonspecific background phosphorylation and to facilitate
the exposure of membrane-bound cGK II to the exogenous substrate, 1%
Triton X-100 and 0.5 M NaCl were added to all fractions prior to assay.
Thermostability Assays—Homogenized cells (15-ml aliquots contain-
ing 15–30 mg of protein) were incubated for 3 min at various tempera-
tures prior to determination of protein kinase activity by incubation for
5 min at 30 °C with the phosphorylation mixture (25 ml) described above
additionally containing 0.3% Triton X-100.
RESULTS AND DISCUSSION
High speed centrifugation of homogenates of HEK 293 cells
stably expressing rat cGK II resulted in recovery of 90–95% of
expressed cGK II in the membrane fraction as detected by
Western blotting (cf. Fig. 3). The enzyme could be released from
the membranes by a combination of detergent (1% Triton
X-100) and high salt (0.5 M NaCl) but not by detergent (Fig. 1)
or high salt alone (not shown). This suggests that recombinant
cGK II is attached both to the membrane and the cytoskeleton
in HEK 293 cells, resembling native cGK II in rat or pig
intestinal brush-border membranes (3), and argues against the
need for an intestine-specific factor for targeting the enzyme to
the membrane. Conceivably, membrane attachment could oc-
cur through cGK II binding to a more ubiquitous anchor. How-
ever, we did not detect any proteins associated with cGK II in
immunoprecipitates from HEK 293 cells metabolically labeled
with [35S]methionine (Fig. 2A). Furthermore, native cGK II
still displays hydrophobic properties after its solubilization and
purification (3). Therefore, the membrane binding of cGK II is
unlikely to depend solely on its association with anchor
proteins.
The alternative possibility that cGK II may be lipid-modified
was tested by incubating HEK 293 cells stably expressing cGK
II with [3H]myristate. As shown in Fig. 2B, a protein with the
correct Mr (86,000) for cGK II was the major radioactively
labeled protein in a total lysate. This myristoylated protein
could be precipitated with a cGK II specific antibody, further
confirming its identity as cGK II. No evidence was obtained for
a second covalent modification by palmitoylation, since no ra-
dioactivity was detected in cGK II immunoprecipitated from
transfected 293 cells metabolically labeled with [3H]palmitate
(not shown).
In order to investigate whether myristoylation plays a role in
the membrane attachment of cGK II, the cGK II-expressing 293
cells were incubated for 48 h with a 1 mM concentration of the
myristoylation inhibitor 2-hydroxymyristic acid (18). Inhibitor
treatment significantly increased the amount of cGK II recov-
ered in the cytosolic fraction (35 6 4%) compared with that of
control cells (10 6 5%) (n 5 5 for each group; Fig. 3). Metabolic
labeling of the cells with [3H]myristate in the presence of
2-hydroxymyristic acid showed that the form of cGK II accu-
mulating in the cytosol was nonmyristoylated (Fig. 3), indicat-
ing that shift in cGK II topology from the membrane to the
cytosol was indeed due to inhibition of myristoylation. High
salt (0.5 M NaCl) had no effect on the amount of cGK II recov-
ered in the cytosol fraction of cells preincubated with 2-hy-
droxymyristic acid, indicating that the fraction of cGK II which
remained bound to the membrane was anchored by hydropho-
bic interactions.The lack of a complete reallocation of cGK II to
the cytosol most likely reflects an incomplete blockade of myr-
istoylation by the inhibitor, since [3H]myristate incorporation
was still detectable in the membrane-bound cGK II pool after
treatment with 2-hydroxymyristic acid (Fig. 3).
To further investigate the membrane binding properties of
nonmyristoylated cGK II, we mutated the penultimate glycine
to an alanine. As shown in Fig. 4A, this G2A mutant, in con-
FIG. 1. Western blot demonstrating that solubilization of cGK
II requires high salt in combination with Triton X-100. HEK 293
cells stably transfected with pRc/CMV-cGK II were homogenized and
centrifuged at 20,000 3 g to obtain a heavy membrane fraction which
was then incubated with 1% Triton X-100 for 5 min at 0 °C in the
presence of various concentrations of NaCl as indicated. Subsequently,
samples were removed before and after centrifugation (15 min, 20,000
3 g) for detection of cGK II present in the total extract (tot) and
supernatant (sup) and pellet (pel) fractions by immunoblotting. The
results shown are representative of three experiments.
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trast to wild type cGK II, was unable to incorporate [3H]my-
ristate after transient expression in COS-1 cells, although wild
type and mutant cGK II were expressed to similar levels as
detected by immunoblotting (Fig. 4B). As observed earlier in
HEK 293 and intestinal cells, wild type cGK II was predomi-
nantly bound to the membrane fraction of COS-1 cells (Fig. 4C).
The removal of Gly2, however, resulted in the shift of a major
proportion of cGK II from a membrane to a cytosolic localiza-
tion (Fig. 4C), providing further evidence that myristoylation is
required for membrane binding of cGK II. The small amount of
the G2A-cGK II mutant recovered in the membrane fraction
most plausibly represents cytosolic enzyme entrapped in in-
completely lysed cells or in vesiculated membranes.
Paradoxically, mouse brain cGK II, which displays a high
level of homology to rat intestine cGK II (4, 5), was reported to
reside predominantly (98%) in the cytosol when expressed in
COS-1 cells (5). This subcellular localization of mouse cGK II,
however, was based on measurements of protein kinase activ-
ity rather than on immunological detection. Therefore, we com-
pared the kinase activities of rat cGK II and the G2A mutant in
the homogenate, cytosolic, and membrane fraction of COS-1
cells. As shown in Fig. 5, only a small proportion of the cGK II
activity was present in the cytosol compared to the membrane
fraction of COS-1 transfected with wild type cGK II, whereas
most of the activity of the nonmyristoylated G2A mutant was
cytosolic. The kinase activities correlated well with the levels of
immunodetectable cGK II in the various fractions (compare
Figs. 4 and 5), indicating that the specific activity of the my-
ristoylated and nonmyristoylated forms of cGK II are not sub-
stantially different. Likewise, the absence of a myristoyl group
did not alter the Ka for cGMP (0.7 mM for both wild type cGK II
and the G2A mutant; Fig. 6). The Ka for cGMP observed here
for rat cGK II resembles the Ka (0.3 mM) reported for mouse
brain cGK II (5). These data therefore failed to provide a clear
explanation for the difference in localization found for rat and
mouse cGK II transiently expressed in COS-1 cells. A species
difference in cGK II membrane anchoring properties was also
considered, but found unlikely because: (i) the first nine amino
acids of mouse brain and rat intestine cGK II, which cover the
region normally containing the myristoylation sequence are
identical, and (ii) native cGK II from rat and mouse intestine as
well as from rat brain were found to be largely membrane-
associated (data not shown).
While these results indicate that myristoylation is a prereq-
uisite for membrane binding of cGK II, additional factors might
contribute as well. Some myristoylated proteins like the cata-
lytic subunit of cAK are soluble (19), or reversibly attached to
the membrane (e.g. MARCKS; Ref. 20). Therefore, a second
membrane binding motif in combination with the myristoyl
group is thought to be required for membrane attachment (21).
This second motif was shown to be either a polybasic region,
which interacts with the negatively charged inner membrane
surface, or a second lipid moiety like palmitic acid (21). No
evidence for palmitoylation of cGK II was obtained in this
FIG. 2. Autoradiogram of cGK II immunoprecipitated from
HEK 293 cells metabolically labeled with [35S]methionine or
[3H]myristate. A, HEK 293 cells mock-transfected or stably trans-
fected with pRc/CMV-cGK II were incubated for 4 h with [35S]methi-
onine and lysed with 1% Triton X-100 and 0.5 M NaCl. cGK II was
immunoprecipitated with a specific antibody and analyzed using 10%
SDS-PAGE and autoradiography (4 days). B, HEK 293 cells stably
transfected with pRc/CMV-cGK II were incubated for 4 h with [3H]my-
ristate, lysed with 1% Triton X-100 and 0.5 M NaCl, and analyzed by
10% SDS-PAGE prior to (lys) or after immunoprecipitation (IP) with
cGK II antibody. Label incorporated was detected by autoradiography
(30 days).
FIG. 3. 2-Hydroxymyristic acid promotes cytosolic localization
of cGK II by inhibiting myristoylation. HEK 293 cells stably trans-
fected with pRc/CMV-cGK II were incubated for 48 h with or without 1
mM myristoylation inhibitor 2-hydroxymyristic acid (HMA). Subse-
quently, cells were either homogenized and cGK II was determined in
the homogenate (hom), cytosolic (cyt), and membrane (mem) fractions
by immunoblotting (lower panel) or cells were incubated for an addi-
tional 4 h with [3H]myristate prior to homogenization and separation
into a cytosolic or membrane fractions. Incorporation of [3H]myristate
into cGK II was detected by autoradiography (20 days) following im-
munoprecipitation of cGK II and subsequent separation on 7.5% SDS-
PAGE (upper panel).
FIG. 4. Localization of the nonmyristoylated cGK II mutant
G2A in COS-1 cells. COS-1 cells were transiently transfected with
pRc/CMV-cGK II (wt) or a mutant-cGK II in which Gly2 was changed to
Ala (G2A). A and B, 2 days after transfection, cells were labeled with
[3H]myristate and cGK II was immunoprecipitated and analyzed by
SDS-PAGE followed by autoradiography (20 days) (A) or immunoblot-
ting (B). C, 2 days after transfection, cGK II was determined in the
homogenate (H), cytosolic (C), and membrane (M) fractions by
immunoblotting.
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study. However, cGK II, similar to cGK I (2), appears to func-
tion as a dimer under physiological conditions,2 suggesting that
two myristoyl groups per molecule of cGKII are available for
membrane binding. The first three lysines in cGKII (Lys7, Lys9,
Lys12), located at similar positions as the lysines involved in
membrane binding of Src (21), may also contribute to the mem-
brane binding.
In addition to its role in membrane anchoring, myristoyla-
tion was also reported to enhance the stability of certain pro-
teins. Notably, the myristoylated catalytic subunit of cAK is
considerably less temperature-sensitive compared to the non-
myristoylated form (22). We therefore compared the thermal
stability of cGK II and the nonmyristoylated G2A mutant. As
shown in Fig. 7, G2A was slightly more stable than wild type
cGK II (1.5–2 °C), indicating that myristoylation does not sta-
bilize cGK II. This suggests that the myristoyl group in cGK II,
in contrast to its counterpart in the catalytic subunit of cAK
(23), is not involved in intramolecular stabilization, but is fully
accessible to membrane interaction.
Conceivably, the intrinsic hydrophobicity of myristoylated
cGK II promotes its association with membrane-bound sub-
strates. Two physiologically relevant substrates of cGK II have
been described so far, i.e. a 25-kDa proteolipid detected in
intestinal brush-border membranes whose function is still un-
known (24), and the CFTR-Cl channel, which is responsible for
the cGMP-mediated electrogenic chloride secretion in the in-
testine (8, 12). Interestingly, purified cGK II, but not cGK Ia, is
able to activate the CFTR-Cl channel in excised membrane
patches of cells stably expressing CFTR (12), whereas both isotypes phosphorylate immunoprecipitated CFTR in vitro (12,
25). Since the N terminus of cGK Ia is acetylated rather than
myristoylated (26), it is tempting to speculate that the different2 A. B. Vaandrager, unpublished results.
FIG. 6. Activation of cGK II and the nonmyristoylated cGK II
mutant G2A by cGMP. COS-1 cells were transiently transfected with
either pRc/CMV-cGK II (WT; l), a cGK II mutant in which Gly2 was
changed to Ala (G2A; M), or the pRc/CMV vector (cont; E). Two days
after transfection, cells were harvested and homogenized. Kinase activ-
ity in the presence of various concentrations of cGMP was determined
in the homogenates after solubilization of cGK II with 1% Triton and 0.5
M NaCl, as described under “Experimental Procedures.” Data are ex-
pressed as means 6 S.E. of three experiments.
FIG. 7. Temperature sensitivity of cGK II and the nonmyris-
toylated cGK II mutant G2A. COS-1 cells were transiently trans-
fected with either pRc/CMV-cGK II (wt; l) or with a cGK II mutant in
which Gly2 was changed to Ala (G2A; E). Two days after transfection,
cells were harvested and homogenized. The homogenates were incu-
bated for 3 min at various temperatures prior to determination of
kinase activity in the presence or absence of 10 mM cGMP for 5 min at
30 °C as described under “Experimental Procedures.” The cGMP-stim-
ulated kinase activity is expressed as a percentage of the cGMP-stim-
ulated kinase activity in homogenates which were preincubated for 1
min at 30 °C prior to the kinase assay. Data are expressed as means 6
S.E. of three experiments.
FIG. 5. Subcellular distribution of the kinase activity of cGK II
and the nonmyristoylated cGK II mutant G2A. COS-1 cells were
transiently transfected with either pRc/CMV-cGK II (wt), a cGK II
mutant in which Gly2 was changed to Ala (G2A), or the pRc/CMV
vector. Two days after transfection, cells were harvested, homogenized,
and fractionated. Kinase activity in the presence or absence of cGMP (5
mM) was determined after solubilization of cGK II with 1% Triton and
0.5 M NaCl, as described under “Experimental Procedures.” cGK II
kinase activity was expressed per mg of homogenate protein and cor-
rected for basal activity found in cells transfected with the pRc/CMV
vector. The basal kinase activities of samples from mock-transfected
COS-1 cells were 92, 94, 13, 17, 61, and 58 pmol/min, respectively, for
the homogenate 2/1-cGMP, the cytosol 2/1-cGMP, and the membrane
fraction 2/1-cGMP. Data are expressed as means 6 S.E. of three
experiments.
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lipidation and membrane binding properties of cGK II and I,
rather than their substrate specificities, account for the pref-
erential activation of CFTR by cGK II. By analogy, modulation
of the a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/
kainate receptor channel by endogenous cAK was shown to be
dependent on the binding of cAK to an anchoring protein,
presumably localized in close proximity to the channel (27).
The availability of a soluble, catalytically active, nonmyris-
toylated mutant version of cGK II may greatly facilitate future
studies designed to investigate the putative role of membrane
anchoring in cGK II regulation of transport functions by a more
direct approach.
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